{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:32:56Z","timestamp":1785785576465,"version":"3.56.0"},"posted":{"date-parts":[[2025,9,18]]},"group-title":"Bioengineering","reference-count":39,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R35GM150689"],"award-info":[{"award-number":["R35GM150689"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/030689123","id-type":"ROR","asserted-by":"publisher"}]},{"name":"National Science Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Lipid nanoparticles (LNPs) administered parenterally often show poor localization to the gastrointestinal (GI) tract and pancreas. In addition, patients typically prefer orally administered drugs to those given intravenously. We therefore investigated whether GI delivery, achievable via device mediated microneedle injections applied to buccal, gastric, small intestinal, colonic, or rectal tissues, could simultaneously enhance LNP delivery to the GI and pancreas while avoiding intravenous administration. Using a combined approach of formulation optimization and GI delivery site screening, we found that cationic SM-102 LNPs delivered gastrically achieved 7-fold higher pancreas delivery in rodents than intravenous neutral SM-102 LNPs. With dose optimization, gastric LNPs achieved 6000-fold greater pancreas to liver targeting ratios than intravenous LNPs. These results suggest GI microneedle administration can reprogram LNP biodistribution, thereby expanding therapeutic opportunities for both local and systemic nucleic acid delivery.<\/jats:p>","DOI":"10.1101\/2025.09.15.676190","type":"posted-content","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T17:30:17Z","timestamp":1758216617000},"source":"Crossref","is-referenced-by-count":2,"title":["Gastrointestinal delivery of mRNA lipid nanoparticles selectively targets the pancreas"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0526-6524","authenticated-orcid":false,"given":"Abdulraouf M.","family":"Abbas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy","family":"Ghanim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Rudden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avraham","family":"Shakked","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyejin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Dahlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4876-9751","authenticated-orcid":false,"given":"Alex","family":"Abramson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"issue":"1","key":"2025092207501100000_2025.09.15.676190v1.1","first-page":"1","article-title":"Nucleic Acid Drugs: Recent Progress and Future Perspectives","volume":"9","year":"2024","journal-title":"Signal Transduct. Target. Ther"},{"key":"2025092207501100000_2025.09.15.676190v1.2","unstructured":"FDA, \u201cFDA Approves Drug to Reduce Triglycerides in Adult Patients with Familial Chylomicronemia Syndrome,\u201d FDA. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-drug-reduce-triglycerides-adult-patients-familial-chylomicronemia-syndrome."},{"key":"2025092207501100000_2025.09.15.676190v1.3","unstructured":"FDA, \u201cMNEXSPIKE,\u201d FDA. https:\/\/www.fda.gov\/vaccines-blood-biologics\/mnexspike."},{"key":"2025092207501100000_2025.09.15.676190v1.4","doi-asserted-by":"crossref","first-page":"eadu1493","DOI":"10.1126\/scitranslmed.adu1493","article-title":"Oral Delivery of Liquid mRNA Therapeutics by an Engineered Capsule for Treatment of Preclinical Intestinal Disease","volume":"17","year":"2025","journal-title":"Sci. Transl. Med"},{"key":"2025092207501100000_2025.09.15.676190v1.5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.09.016"},{"key":"2025092207501100000_2025.09.15.676190v1.6","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.2147\/IJN.S116902","article-title":"RNA Interference-Based Nanosystems for Inflammatory Bowel Disease Therapy","volume":"11","year":"2016","journal-title":"Int. J. Nanomedicine"},{"key":"2025092207501100000_2025.09.15.676190v1.7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.omtn.2018.09.010","article-title":"Synthetic Circular RNA Functions as a miR-21 Sponge to Suppress Gastric Carcinoma Cell Proliferation","volume":"13","year":"2018","journal-title":"Mol. Ther. Nucleic Acid"},{"key":"2025092207501100000_2025.09.15.676190v1.8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.18688"},{"key":"2025092207501100000_2025.09.15.676190v1.9","doi-asserted-by":"crossref","first-page":"50802","DOI":"10.1021\/acsami.1c16151","article-title":"Tetrahedral Framework Nucleic Acids Reverse New-Onset Type 1 Diabetes","volume":"13","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2025092207501100000_2025.09.15.676190v1.10","doi-asserted-by":"crossref","first-page":"102440","DOI":"10.1016\/j.omtn.2024.102440","article-title":"Nucleic Acid Therapeutics: Past, Present, and Future","volume":"36","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2025092207501100000_2025.09.15.676190v1.11","doi-asserted-by":"crossref","first-page":"1907233","DOI":"10.1002\/smll.201907233","article-title":"Efficient Gene Therapy of Pancreatic Cancer via a Peptide Nucleic Acid (PNA)-Loaded Layered Double Hydroxides (LDH) Nanoplatform","volume":"16","year":"2020","journal-title":"Small"},{"key":"2025092207501100000_2025.09.15.676190v1.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-017-0043-5"},{"key":"2025092207501100000_2025.09.15.676190v1.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-025-01954-9"},{"key":"2025092207501100000_2025.09.15.676190v1.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-020-0669-6"},{"key":"2025092207501100000_2025.09.15.676190v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2022.03.046"},{"key":"2025092207501100000_2025.09.15.676190v1.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-021-00786-x"},{"key":"2025092207501100000_2025.09.15.676190v1.17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.addr.2020.06.003","article-title":"Dawn of Lipid Nanoparticles in Lymph Node Targeting: Potential in Cancer Immunotherapy","volume":"167","year":"2020","journal-title":"Adv. Drug Deliv. Rev"},{"key":"2025092207501100000_2025.09.15.676190v1.18","doi-asserted-by":"publisher","DOI":"10.1007\/S13346-025-01961-2"},{"key":"2025092207501100000_2025.09.15.676190v1.19","doi-asserted-by":"crossref","unstructured":"Melamed, J. R. , et al., \u201cIonizable Lipid Nanoparticles Deliver mRNA to Pancreatic \u03b2 Cells via Macrophage-Mediated Gene Transfer,\u201d Sci. Adv. 9 (2023).","DOI":"10.1126\/sciadv.ade1444"},{"key":"2025092207501100000_2025.09.15.676190v1.20","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau2277"},{"key":"2025092207501100000_2025.09.15.676190v1.21","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.matt.2021.12.022","article-title":"Oral mRNA Delivery Using Capsule-Mediated Gastrointestinal Tissue Injections","volume":"5","year":"2022","journal-title":"Matter"},{"key":"2025092207501100000_2025.09.15.676190v1.22","first-page":"103","article-title":"Oral Delivery of Systemic Monoclonal Antibodies, Peptides and Small Molecules Using Gastric Auto-Injectors","volume":"40","year":"2021","journal-title":"Nat. Biotechnol"},{"key":"2025092207501100000_2025.09.15.676190v1.23","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24182"},{"key":"2025092207501100000_2025.09.15.676190v1.24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41586-024-08202-5","article-title":"Cephalopod-Inspired Jetting Devices for Gastrointestinal Drug Delivery","volume":"636","year":"2024","journal-title":"Nature"},{"key":"2025092207501100000_2025.09.15.676190v1.25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10198-010-0224-8","article-title":"Utilities and Disutilities for Attributes of Injectable Treatments for Type 2 Diabetes","volume":"12","year":"2011","journal-title":"Eur. J. Health Econ"},{"key":"2025092207501100000_2025.09.15.676190v1.26","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2147\/PPA.S463354","article-title":"Preference for a Novel Oral Alternative to Parenterally Administered Medications","volume":"18","year":"2024","journal-title":"Patient Prefer. Adherence"},{"key":"2025092207501100000_2025.09.15.676190v1.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.01.008"},{"key":"2025092207501100000_2025.09.15.676190v1.28","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/s41586-025-09304-4","article-title":"Mechanical Underwater Adhesive Devices for Soft Substrates","volume":"643","year":"2025","journal-title":"Nature"},{"key":"2025092207501100000_2025.09.15.676190v1.29","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1053\/j.gastro.2017.01.002","article-title":"Ultrasound-Mediated Delivery of RNA to Colonic Mucosa of Live Mice","volume":"152","year":"2017","journal-title":"Gastroenterology"},{"key":"2025092207501100000_2025.09.15.676190v1.30","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/s41551-025-01360-5","article-title":"Radioprotection of Healthy Tissue via Nanoparticle-Delivered mRNA Encoding for a Damage-Suppressor Protein Found in Tardigrades","volume":"9","year":"2025","journal-title":"Nat. Biomed. Eng"},{"key":"2025092207501100000_2025.09.15.676190v1.31","doi-asserted-by":"crossref","first-page":"2404830","DOI":"10.1002\/adma.202404830","article-title":"pH-Responsive \u03b2-Glucans-Complexed mRNA in LNPs as an Oral Vaccine for Enhancing Cancer Immunotherapy","volume":"36","year":"2024","journal-title":"Adv. Mater"},{"key":"2025092207501100000_2025.09.15.676190v1.32","doi-asserted-by":"crossref","first-page":"121707","DOI":"10.1016\/j.biomaterials.2022.121707","article-title":"Oral Delivery of IL-22 mRNA-Loaded Lipid Nanoparticles Targeting the Injured Intestinal Mucosa: A Novel Therapeutic Solution to Treat Ulcerative Colitis","volume":"288","year":"2022","journal-title":"Biomaterials"},{"key":"2025092207501100000_2025.09.15.676190v1.33","first-page":"369","article-title":"Species-Agnostic Polymeric Formulations for Inhalable Messenger RNA Delivery to the Lung","volume":"22","year":"2022","journal-title":"Nat. Materials"},{"key":"2025092207501100000_2025.09.15.676190v1.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.08.007"},{"key":"2025092207501100000_2025.09.15.676190v1.35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45766-2"},{"key":"2025092207501100000_2025.09.15.676190v1.36","doi-asserted-by":"publisher","DOI":"10.1038\/nature07314"},{"key":"2025092207501100000_2025.09.15.676190v1.37","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1038\/s41467-025-58548-1","article-title":"Nanoparticle Delivery of a Prodrug-Activating Bacterial Enzyme Leads to Anti-Tumor Responses","volume":"16","year":"2025","journal-title":"Nat. Commun"},{"key":"2025092207501100000_2025.09.15.676190v1.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.01.002"},{"key":"2025092207501100000_2025.09.15.676190v1.39","doi-asserted-by":"crossref","unstructured":"Tiwari, P. M. , et al., \u201cEngineered mRNA-Expressed Antibodies Prevent Respiratory Syncytial Virus Infection,\u201d Nat. Commun. 9 (2018).","DOI":"10.1038\/s41467-018-06508-3"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.09.15.676190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T09:36:37Z","timestamp":1768469797000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2025.09.15.676190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":39,"URL":"https:\/\/doi.org\/10.1101\/2025.09.15.676190","relation":{},"subject":[],"published":{"date-parts":[[2025,9,18]]},"subtype":"preprint"}}